Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Advances in early-stage lung cancer patients: from preanalytics to molecular analysis.

Critical reviews in oncology/hematology·2026

Same author

PLGA/PVA nanoparticles to deliver a protein-based cancer vaccine targeting GPC1 for the treatment of pancreatic ductal adenocarcinoma.

Nanomedicine (London, England)·2026

Same author

Mast cell release of TNF-α indirectly contributes to recalling B cells in the colorectal cancer milieu through the CCL20/CCR6 axis.

Frontiers in immunology·2026

Same author

Morphology first: preserving diagnostic hierarchies in high-grade neuroendocrine neoplasms across organ sites.

Endocrine·2026

Same author

Rethinking the prognostic and biological significance of neuroendocrine marker expression in colorectal carcinoma.

Frontiers in endocrinology·2026

Same author

Impact of Sarcopenia and Serum Creatinine on Clinical Outcomes after Tace in Hepatocellular Carcinoma.

Journal of Cancer·2026

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular

Monica Mossenta^1,2, Monica Argenziano³, Sara Capolla¹

¹Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico (CRO) di Aviano IRCCS, Aviano, Italy.

Nanomedicine (London, England)

|January 15, 2025

Summary

Chitosan nanobubbles loaded with idarubicin offer a promising strategy for hepatocellular carcinoma (HCC) treatment. These nanobubbles effectively target tumors, reduce side effects, and improve survival rates in preclinical models.

Keywords:

Hepatocellular carcinoma antibody conjugation, glypican 3 chitosan drug delivery idarubicin nanobubbles

More Related Videos

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Related Experiment Videos

Last Updated: Jun 17, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Area of Science:

Biomedical Engineering
Nanotechnology
Oncology

Background:

Hepatocellular carcinoma (HCC) treatment can be improved by targeted drug delivery systems.
Chitosan nanobubbles (CS-NBs) offer a potential platform for reducing drug toxicity and enhancing therapeutic outcomes.
Targeting agents, like antibodies, can be conjugated to nanocarriers to improve tumor accumulation.

Purpose of the Study:

To investigate the efficacy of idarubicin-loaded chitosan nanobubbles (CS-NBs) for hepatocellular carcinoma (HCC) treatment.
To evaluate the role of a GC33-derived minibody (4A1) in enhancing the delivery and efficacy of CS-NBs.
To assess the impact of these targeted nanobubbles on tumor growth, survival, and drug side effects in preclinical models.

Main Methods:

Preparation of various chitosan nanobubble (CS-NB) formulations with and without idarubicin loading and 4A1 conjugation.
In vitro cytotoxicity assessment using the HCC-like HUH7 cell line.
In vivo biodistribution and anti-tumor efficacy studies in HUH7 tumor-bearing xenograft mice.

Main Results:

Chitosan nanobubbles (CS-NBs) exhibited positive charge and a diameter of approximately 360 nm.
Idarubicin-loaded CS-NBs demonstrated significant in vitro cytotoxicity against HUH7 cells.
In vivo studies showed enhanced tumor accumulation of CS-NBs with 4A1 conjugation (p=0.0317) and significant tumor growth inhibition and increased survival in mice compared to free idarubicin (p=0.00044 and p=0.0018).

Conclusions:

Idarubicin-loaded chitosan nanobubbles (CS-NBs) represent a viable drug delivery strategy for hepatocellular carcinoma (HCC).
The addition of the 4A1 minibody enhances tumor targeting and therapeutic outcomes.
CS-NBs effectively reduce drug side effects while improving treatment efficacy in preclinical HCC models.